Aller au contenu

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Nom du journal : The Lancet Oncology

Année : 2021

Volume : 22

Page de départ : 1721

Page de fin : 1731

Auteurs: Bradley WH, González-Martín A, DiSilvestro P, Lowe ES, Aghajanian C, Oza A, Banerjee S, Gourley C, Lisyanskaya A, Oaknin A, Moore KN, Leary A, Kim BG, Colombo N, Sonke GS, Friedlander M, Scambia G, Floquet A, Holmes E,